13F reference period
Q3 2026
CUSIP: 68622P109
13F reference period
Q3 2026
Institutions Reporting
147
Shares (Excl. Options)
Price
$13.47
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 147 institutions filings for Q3 2026.
Security key
68622P109
13F reference period
Q3 2026
13F holders
147
13D/G owners
12
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 68622P109:
13D/G owners
Large-stake holder rows connected to Schedule 13D/G evidence.
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Nextech Crossover I GP S.a r.l. | 8.4% | $78,072,743 | 7,162,637 | Nextech Crossover I GP S.a. r.l. | 30 Jun 2025 | |||
| VIKING GLOBAL INVESTORS LP | 5.7% | -26% | $82,721,188 | -$31,165,096 | 6,002,989 | -27% | VIKING GLOBAL INVESTORS LP | 30 Sep 2026 |
| BlackRock, Inc. | 5.6% | +35% | $44,773,610 | +$15,158,006 | 5,473,145 | +51% | BlackRock, Inc. | 31 Dec 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.9% | -10% | $60,095,126 | -$3,534,591 | 5,088,495 | -5.6% | T. Rowe Price Associates, Inc. | 30 Sep 2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | 4.8% | -13% | $50,307,686 | 4,615,384 | 0% | SR One Capital Management, LLC | 12 Aug 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC | 4.6% | $54,049,152 | 4,504,096 | Alkeon Capital Management LLC | 30 Sep 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 4.2% | -27% | $44,925,556 | -$14,107,236 | 4,319,765 | -24% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
| COLUMN GROUP II, LP | 3.7% | $48,612,534 | 3,644,118 | Peter Svennilson | 30 Sep 2025 | |||
| PFIZER INC | 3.3% | $35,806,576 | 3,442,940 | Pfizer Inc. (IRS Identification No.: 13-5315170) | 31 Mar 2026 | |||
| EcoR1 Capital, LLC | 2.9% | -57% | $35,762,050 | -$43,697,000 | 3,028,116 | -55% | EcoR1 Capital, LLC | 30 Sep 2026 |
| FMR LLC | 3.5% | $13,967,797 | 2,467,809 | FMR LLC | 31 Dec 2024 | |||
| Frazier Life Sciences Public Fund, L.P. | 2% | $7,981,692 | 1,410,193 | James N. Topper | 31 Mar 2025 |
13F concentration
Largest 13F positions for this security by reported shares and value.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Nextech Invest Ltd. | 6.8% | 7,162,637 | 4.3% | $96,480,720 | |
| AIHC Capital Management Ltd | 4.4% | 4,630,986 | 57% | $62,379,381 | |
| SR ONE CAPITAL MANAGEMENT, LP | 4.4% | 4,615,384 | 5.4% | $62,169,223 | |
| STATE STREET CORP | 3.9% | 4,126,317 | 0% | $55,581,490 | |
| NEA Management Company, LLC | 3.9% | 4,118,621 | 4.1% | $55,477,825 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 4,072,661 | 0% | $54,858,744 | |
| VIKING GLOBAL INVESTORS LP | 3.4% | 3,562,915 | 0.15% | $47,992,465 | |
| Column Group LLC | 3.4% | 3,540,777 | 38% | $47,694,266 | |
| Siren, L.L.C. | 3.2% | 3,358,192 | 1.1% | $45,234,846 | |
| ALKEON CAPITAL MANAGEMENT LLC | 3.1% | 3,239,096 | 0.18% | $43,630,623 | |
| EcoR1 Capital, LLC | 2.9% | 3,028,116 | 2% | $40,788,723 | |
| Venrock Adviser, LLC | 2.8% | 2,944,056 | 1.9% | $39,656,434 | |
| Defilade Capital Management, L.P. | 2.2% | 2,272,497 | 5.1% | $30,610,535 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 2,193,715 | 0% | $29,555,467 | |
| DIMENSIONAL FUND ADVISORS LP | 1.8% | 1,900,144 | 0% | $25,594,064 | |
| MPM BIOIMPACT LLC | 1.7% | 1,821,951 | 1.9% | $24,541,680 | |
| GOLDMAN SACHS GROUP INC | 1.7% | 1,801,571 | 0% | $24,267,162 | |
| Integral Health Asset Management, LLC | 1.6% | 1,700,000 | 1.3% | $20,205,000 | |
| Qube Research & Technologies Ltd | 1.6% | 1,642,227 | 0.02% | $22,120,798 | |
| ALGERT GLOBAL LLC | 1.5% | 1,621,908 | 0.26% | $21,847,101 | |
| First Turn Management, LLC | 1.5% | 1,574,334 | 2.8% | $21,206,279 | |
| ORBIMED ADVISORS LLC | 1.5% | 1,555,900 | 0.38% | $20,957,973 | |
| Paradigm Biocapital Advisors LP | 1.4% | 1,505,769 | 0.4% | $20,282,708 | |
| Woodline Partners LP | 1.4% | 1,433,961 | 0.06% | $19,315,455 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.2% | 1,286,565 | 0.02% | $17,330,031 |
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 93,303,546 | $1,246,181,814 | -$58,072,530 | $13.47 | 147 |
| 2026 Q2 | 123,545,907 | $1,337,403,876 | +$37,483,837 | $10.83 | 179 |
| 2026 Q1 | 119,358,492 | $1,509,867,722 | +$11,113,839 | $12.67 | 182 |
| 2025 Q4 | 119,654,372 | $979,584,067 | +$96,243,084 | $8.18 | 166 |
| 2025 Q3 | 106,492,104 | $1,277,897,818 | +$159,574,138 | $12.00 | 151 |
| 2025 Q2 | 93,349,298 | $947,499,065 | +$169,716,912 | $10.15 | 140 |
| 2025 Q1 | 79,209,337 | $442,004,992 | +$11,923,513 | $5.58 | 142 |
| 2024 Q4 | 75,794,185 | $611,682,254 | -$16,308,147 | $8.07 | 129 |
| 2024 Q3 | 69,823,199 | $715,076,569 | +$22,655,622 | $10.25 | 121 |
| 2024 Q2 | 67,575,796 | $477,762,911 | +$20,174,043 | $7.07 | 111 |
| 2024 Q1 | 63,945,767 | $879,254,046 | +$197,777,720 | $13.75 | 110 |
| 2023 Q4 | 50,638,764 | $465,880,631 | +$34,655,080 | $9.20 | 91 |
| 2023 Q3 | 48,053,106 | $290,723,321 | +$14,148,790 | $6.05 | 89 |
| 2023 Q2 | 45,537,877 | $353,374,535 | +$99,111,683 | $7.76 | 83 |
| 2023 Q1 | 33,075,099 | $188,527,951 | +$3,515,469 | $5.70 | 70 |
| 2022 Q4 | 32,430,291 | $192,141,081 | +$135,543 | $5.89 | 64 |
| 2022 Q3 | 32,701,288 | $104,643,704 | -$1,866,676 | $3.20 | 69 |
| 2022 Q2 | 32,837,327 | $147,127,000 | -$6,223,365 | $4.48 | 77 |
| 2022 Q1 | 33,856,070 | $180,750,917 | -$7,186,800 | $5.34 | 94 |
| 2021 Q4 | 34,857,324 | $512,119,938 | -$36,775,082 | $14.70 | 79 |
| 2021 Q3 | 31,534,174 | $659,370,855 | +$8,490,366 | $20.91 | 78 |
| 2021 Q2 | 36,145,561 | $639,409,737 | +$2,954,162 | $17.69 | 78 |
| 2021 Q1 | 35,685,685 | $874,284,848 | +$71,774,159 | $24.50 | 82 |
| 2020 Q4 | 32,607,853 | $1,103,814,951 | +$273,075,064 | $33.85 | 76 |
| 2020 Q3 | 22,151,969 | $552,859,000 | +$7,647,968 | $25.01 | 53 |